Literature DB >> 11745260

Antibody response to Epstein-Barr virus Rta protein in patients with nasopharyngeal carcinoma: a new serologic parameter for diagnosis.

P Feng1, S H Chan, M Y Soo, D Liu, M Guan, E C Ren, H Hu.   

Abstract

BACKGROUND: Nasopharyngeal carcinoma (NPC) is associated closely with Epstein-Barr virus (EBV). The authors previously reported that an EBV immediate-early gene, BRLF1, was expressed frequently in NPC tumors, and a significant elevation in immunoglobulin G (IgG) antibodies directed against BRLF1 gene product Rta was detected in NPC sera by a radioactive immunoprecipitation assay. To simplify and to make the detection more quantitative, an enzyme-linked immnunosorbent assay (ELISA) was developed in this study.
METHODS: Antigen domains of Rta were identified further using an immunoprecipitation assay. Two glutathione-S-transferase (GST) recombinant Rta fragments (R150-GST and R185-GST) were prepared subsequently and were used as antigens in the ELISA. Serum samples derived from 51 patients with NPC patients, 115 non-NPC ENT patients, and 47 healthy volunteers were examined for the presence of antibodies directed against Rta.
RESULTS: Among the patients with NPC, 74.5% showed a positive IgG response to R150-GST, and 62.7% showed a positive IgG response to R185-GST, with 80.4% positive for either fragment. In contrast, the reactions were positive in only 8.5% of healthy volunteers and 13.0% of control patients. When using a mixture of the two recombinant Rta proteins as coating antigens, the IgG positive responses were 82.3%, 10.6%, and 14.8%, respectively, in patients with NPC, healthy volunteers, and control patients. It is noteworthy that 51.0% of the NPC sera showed a positive immunoglobulin A (IgA) response, with none of the control patients showing obvious reactivity. Both the IgG response and the IgA response to Rta protein in patients with NPC were correlated with the IgA response to EBV early antigens and virus capsid antigens, the classic serologic markers used to diagnose NPC.
CONCLUSIONS: The ELISA method described for the detection of IgG antibodies directed against recombinant Rta proteins is simple and reliable and may be useful as a serologic parameter for the screening and diagnosis of patients with NPC. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745260     DOI: 10.1002/1097-0142(20011001)92:7<1872::aid-cncr1704>3.0.co;2-n

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Recombinant protein-based enzyme-linked immunosorbent assay and immunochromatographic tests for detection of immunoglobulin G antibodies to severe acute respiratory syndrome (SARS) coronavirus in SARS patients.

Authors:  Ming Guan; Hsiao Ying Chen; Shen Yun Foo; Yee-Joo Tan; Phuay-Yee Goh; Shock Hwa Wee
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

Review 2.  Serodiagnosis for tumor viruses.

Authors:  Brian J Morrison; Nazzarena Labo; Wendell J Miley; Denise Whitby
Journal:  Semin Oncol       Date:  2014-12-31       Impact factor: 4.929

3.  Epstein-Barr virus transcription activator Rta upregulates decoy receptor 3 expression by binding to its promoter.

Authors:  Cheng-Hsun Ho; Chen-Fang Hsu; Pei-Fen Fong; Shyh-Kuan Tai; Shie-Liang Hsieh; Chi-Ju Chen
Journal:  J Virol       Date:  2007-02-14       Impact factor: 5.103

4.  Combination of Plasma MIF and VCA-IgA Improves the Diagnostic Specificity for Patients With Nasopharyngeal Carcinoma.

Authors:  Ning Xue; Shan Xing; Weiguo Ma; Jiahe Sheng; Zhiliang Huang; Qingxia Xu
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

5.  Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology.

Authors:  Ai-Di Gu; Li-Xia Lu; Yan-Bo Xie; Li-Zhen Chen; Qi-Sheng Feng; Tiebang Kang; Wei-Hua Jia; Yi-Xin Zeng
Journal:  J Transl Med       Date:  2009-08-23       Impact factor: 5.531

6.  Epstein-Barr virus BRLF1 induces genomic instability and progressive malignancy in nasopharyngeal carcinoma cells.

Authors:  Sheng-Yen Huang; Chung-Chun Wu; Yu-Jhen Cheng; Sheng-Ping Chou; Yun-Jin Jiang; Kuo-Chang Chu; Ching-Hwa Tsai; Su-Fang Lin; Jen-Yang Chen
Journal:  Oncotarget       Date:  2017-09-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.